Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

Abstract Introduction Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present pharmacokinetic (PK), efficacy, and safety results fro...

Full description

Bibliographic Details
Main Authors: Himanshu P. Upadhyaya, Jenny Y. Chien, Amanda J. Long, Martin S. Bohm, Nicole L. Kallewaard, Lisa F. Macpherson, Dipak R. Patel, Matthew M. Hufford, Constance J. Krull, Jocelyn Y. Ang, Peter Chen, William J. Muller, Jeffrey A. Potts, Timothy Quinn, Mark Williams, BLAZE-1 Investigators
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Infectious Diseases and Therapy
Subjects:
Bamlanivimab
COVID-19
Etesevimab
Monoclonal antibodies
Pediatric
Pharmacokinetics
Online Access:https://doi.org/10.1007/s40121-023-00832-y

Internet

https://doi.org/10.1007/s40121-023-00832-y

Similar Items